Analyst IMS Investment Management Services Ltd. boosted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 301.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 10,298 shares of the company’s stock after purchasing an additional 7,733 shares during the period. Analyst IMS Investment Management Services Ltd.’s holdings in Merck & Co., Inc. were worth $1,084,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Chemung Canal Trust Co. increased its stake in Merck & Co., Inc. by 21.1% during the 3rd quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after buying an additional 13,285 shares during the period. First Pacific Financial lifted its holdings in Merck & Co., Inc. by 14.7% during the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after buying an additional 6,082 shares in the last quarter. Diversified Trust Co boosted its position in Merck & Co., Inc. by 9.6% in the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock valued at $17,444,000 after buying an additional 18,187 shares during the period. Caxton Associates LLP boosted its position in Merck & Co., Inc. by 23.3% in the 2nd quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock valued at $3,121,000 after buying an additional 7,458 shares during the period. Finally, Coldstream Capital Management Inc. grew its stake in shares of Merck & Co., Inc. by 12.7% in the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after acquiring an additional 13,940 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Merck & Co., Inc. News Roundup
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
- Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
- Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
- Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
- Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
- Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
- Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent
Analyst Upgrades and Downgrades
Read Our Latest Analysis on MRK
Insider Buying and Selling at Merck & Co., Inc.
In related news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard R. Deluca sold 37,685 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This trade represents a 19.05% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.13% of the company’s stock.
Merck & Co., Inc. Stock Down 0.2%
Shares of NYSE MRK opened at $120.62 on Friday. The stock has a market cap of $298.21 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The business has a 50-day moving average price of $117.72 and a 200 day moving average price of $103.08.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same quarter in the previous year, the company posted $1.72 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.
Merck & Co., Inc. Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.
About Merck & Co., Inc.
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Recommended Stories
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
